GENinCode UK Ltd. (GB:GENI) has released an update.
GENinCode UK Ltd has reported a robust first half of 2024 with a 46% revenue increase to £1.39m, buoyed by its first commercial sales in the US and strategic expansions in the UK and Europe. The company has made significant progress with its cardiovascular and ovarian cancer tests, including FDA discussions for its CARDIO inCode-Score® device and NICE’s recommendation for the ROCA test. Looking ahead, GENinCode anticipates continued growth through further market expansion and partnerships.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.
